Company ProfilePremium

Silex Systems Limited

Company Profile Analysis

Ticker: SLX.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Silex Systems Limited - Company showcase

Year Founded & Workforce

1987

Silex Systems Limited logo

Silex Systems Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Silex Systems Limited Overview

Silex Systems is a pre-revenue Australian deep-technology company whose core asset is the SILEX process, a proprietary "third-generation" laser isotope separation technology. The technology was invented at Lucas Heights and is classified by both the Australian and US governments. Silex does not mine or enrich uranium itself. Instead, it commercialises SILEX for uranium through Global Laser Enrichment LLC (GLE), the exclusive licensee, which it owns 51% alongside Cameco (49%). GLE plans to build the Paducah Laser Enrichment Facility (PLEF) in Kentucky. The plant would first re-enrich US Department of Energy (DOE) depleted uranium tails into natural UF6, and later produce LEU, LEU+ and potentially HALEU. The company calls this a "Triple Opportunity" single-site solution.

Silex captures value in three ways: a perpetual royalty of at least 7% on GLE enrichment revenue, up to US$20 million in milestone payments, and its equity share of GLE. Secondary platforms are:

  • Quantum Silicon (Q-Si): enriched silicon-28 for silicon quantum computing

  • Medical Isotope Separation Technology (MIST)

The investment case is binary-leaning. It depends on PLEF licensing (an NRC decision is expected around 2027), the financing and final investment decision (FID), and Cameco's option to step up to 75% of GLE.


Company's own description

In its FY2025 Annual Report and August 2026 Operational Update, Silex describes itself as a technology commercialisation company. Its primary asset is the SILEX laser enrichment technology, originally developed at its Sydney (Lucas Heights) facility. The company states that its strategy is commercialising SILEX across multiple global markets. The primary focus is supplying nuclear fuel reliably and sustainably to the global nuclear power industry, which it describes as a vital enabler of energy security and clean energy (Operational Update, 27 August 2026). Silex lists three application areas:

  1. Uranium enrichment and production (nuclear power), via GLE

  2. Silicon enrichment (Q-Si) for silicon-based quantum computing

  3. Medical isotope enrichment (MIST) for new cancer therapies

Independent characterisation

Value layerMechanismStatus (Oct 2026)
Equity51% of GLE (equity-accounted share of GLE losses flows through Silex P&L)Active; Silex funds 51% of GLE spend
RoyaltyPerpetual royalty of ≥7% on GLE enrichment revenue (per company disclosures)Contingent on PLEF operation (targeted no later than 2030)
MilestonesUp to US$20 million in milestone payments from GLE (pilot demonstration, construction start, commercial operation)US$5 million TRL-6 milestone received December 2025
Option crystallisationCameco holds an option to buy an additional 26% of GLE (to 75%). The window started at TRL-6 and runs ~30 months (Shaw and Partners, July 2026)Open; window expires ~April 2028
Other isotopesQ-Si plant (Lucas Heights); MIST R&DQ-Si commissioning late 2026; first samples expected Q1 CY2027
LegacyTranslucent Inc. (cREO semiconductor materials)Small reporting segment

Silex is effectively an IP-holding and technology-development company whose valuation rests almost entirely on a US joint venture. Silex holds the majority economic interest in that venture, but under the GLE structure Cameco is the commercial lead. Silex's economics come in layers:

Revenue model and mix

Current revenue is not commercial product revenue. "Revenue from ordinary activities" (A$21.6M in FY2026) is mostly:

  • interest income on cash and term deposits

  • the GLE TRL-6 milestone (≈A$7.6M recognised in FY2026)

  • service and cost-recovery income from GLE and other parties

The mix is effectively 100% interest, licensing and milestones, and services, with 0% product sales of scale. Future revenue would shift to licensing (royalty) and equity earnings from GLE. Q-Si could add product sales of enriched silicon if quantum-computing demand develops.

Value-chain position and customers

Nuclear fuel cycle position: Enrichment technology provider. PLEF would also produce natural UF6, adding conversion-equivalent supply because re-enriching tails yields UF6 directly without mining or conversion. Downstream buyers would be utilities. Under the September 2026 Offtake Agreement, Cameco is the exclusive buyer and seller of all PLEF products.

Q-Si customers: Silicon Quantum Computing Pty Ltd (SQC) and other quantum-device researchers.

MIST: Prospective radiopharmaceutical isotope producers (not yet commercial).

End-markets: Nuclear power fuel (natural UF6, LEU, LEU+, HALEU), quantum computing materials, and nuclear medicine.

Strategy

Stated strategy themes (FY2025 Annual Report; Operational Update, 27 August 2026)

  1. Commercialise SILEX for uranium in the US through GLE. The PLEF would be the world's first laser-based uranium enrichment plant and a "single-site solution" for natural UF6, LEU/LEU+ and potentially HALEU.

  2. Support US fuel security and the move away from Russian supply. Silex positions PLEF as the only new enrichment facility under NRC licence review (ASX, 23 October 2025) and as part of rebuilding US domestic capacity.

  3. Diversify SILEX applications. Q-Si for silicon quantum computing and MIST for medical isotopes.

  4. Stay fully funded and debt-free. Funded through FY2028 after the A$149M 2025 raise.

Strategic initiatives (last 24 months)

InitiativeDateDetailStatus
TRL-6 pilot demonstrationMay–Oct 2025Large-scale enrichment testing at WilmingtonAchieved 23 Oct 2025
TRL-7 activitiesFrom late 2025Next maturity stage toward commercial designIn progress
PLEF licensingJun 2025 onwardNRC licence application; EIS by Sep 2026; SER by Jan 2027; mandatory hearingUnder review
PLEF site and preliminary worksFY2025–FY2026~700-acre site acquired; initial site clearingOngoing
US domestic manufacturing baseFY2026Expansion of GLE's classified manufacturing operationsOngoing
DOE innovative technology awardJan 2026Up to US$28.5M non-equity supportContract negotiation/execution
Kentucky incentivesMar 2026Up to US$98.9M, performance-basedPreliminary approval
Cameco Offtake AgreementSep 2026Cameco exclusive buyer/seller of all PLEF outputExecuted; described as a "key commercial pillar" for FID
Q-Si plant2023–2026Construction complete; commissioningSamples Q1 CY2027
MISTOngoingMedical isotope R&DEarly stage
Capital raiseAug–Sep 2025A$130M placement + A$19.4M SPPCompleted

Medium-term targets and guidance

First production: GLE aims to begin re-enriching DOE Paducah tails "no later than 2030" (GLE press release, August 2025). A Shaw and Partners site visit in July 2026 reiterated first uranium production on track for 2030. Earlier guidance (March 2025) preserved an option for PLEF commercial operations "as early as 2028". That date has effectively shifted to around 2030.

Scale: Conceptual potential of up to 6 million SWU per year. The company has also described a goal of supplying around 10% of US reactor requirements (smallcaps.com.au summary of ASX, 6 January 2026).

Funding: Fully funded through FY2028 (ASX, 7 August 2025).

Financial guidance: No formal revenue or earnings guidance is given. Consensus EPS for the next financial year is about -A$0.13 (Stockopedia).

Products & Services

SILEX Laser Uranium Enrichment Technology (via GLE) — Silex USA / Silex Systems

AttributeDetail
DescriptionThird-generation laser isotope separation. Lasers selectively excite U-235-bearing UF6 molecules for separation. The company claims higher enrichment efficiency and throughput, a smaller footprint and lower capital intensity than second-generation gas centrifuges (ASX, 6 Jan 2026; Kalkine summary of company materials)
MaturityTRL-6 achieved and independently validated, 23 October 2025. TRL-7 activities advancing (H1 FY2026 report)
ClassificationClassified technology under the Australia–US cooperation agreement
Target customersUtilities (via Cameco as exclusive offtaker/seller); US Government fuel-security programs
Pricing modelSilex receives a ≥7% royalty on GLE enrichment revenue plus milestones. PLEF product pricing would follow market SWU and UF6 prices
Flagship projectPaducah Laser Enrichment Facility (PLEF), McCracken County, KY
ProductDescriptionNotes
Natural-grade UF6Re-enrichment of DOE high-assay depleted tails to natural assay (0.711% U-235)First commercial priority. Company materials describe conversion-equivalent supply "for up to three decades" (H1 FY2026 report). GLE targets beginning tails re-enrichment no later than 2030
LEU / LEU+Enrichment up to 5% (LEU) and 5–10% (LEU+) for existing and next-generation reactorsRequires additional SILEX capacity. PLEF could reach up to ~6 million SWU per year at full potential (ASX, 23 Oct 2025, company conceptual figure)
HALEU5–20% U-235 for advanced reactorsLonger-dated option. GLE declined the 2025 DOE HALEU RFP

Wilmington Test Loop (GLE)

GLE's integrated pilot demonstration facility in Wilmington, NC (on the GNF-A site under licence SNM-1097) performed the TRL-6 large-scale enrichment testing. GLE also operates a classified manufacturing activity, which it is expanding to build a US domestic supply chain for laser and separator hardware (FY2026 Operational Update).

Quantum Silicon (Q-Si) — Silex Systems segment

AttributeDetail
DescriptionIsotopically enriched silicon-28 ("Zero-Spin Silicon"), produced by the SILEX process applied to silicon, for spin-qubit silicon quantum computers
FacilityFirst full-scale production module at Lucas Heights; construction started Aug 2023 and completed in 2026. Described as the world's first silicon laser enrichment plant (FY2026 investor materials)
StatusCommissioning to complete late 2026; first product samples expected Q1 CY2027
CapacityAggregators cite a target of up to ~20 kg/year of Si-28 from the module (ROIC.ai summary of company materials). Treat as indicative
PartnersSilicon Quantum Computing Pty Ltd (SQC); UNSW Sydney. The collaboration received a 2025 "Best Industry Research Collaboration" award (ROIC.ai summary)
Pricing—
ExpansionModular expansion possible as quantum computing markets develop (FY2026 results)

Medical Isotope Separation Technology (MIST) — Silex Systems segment

MIST is early-stage R&D applying laser isotope separation to medical isotopes for cancer therapies. Company disclosures reference ytterbium-176, the precursor for lutetium-177 radiopharmaceuticals. Specifications, customers, timelines and pricing are not publicly disclosed in the sources reviewed.

Translucent cREO — Translucent segment

Translucent's crystalline rare-earth oxide (cREO) technology is a semiconductor materials technology for engineered substrates, such as GaN-on-silicon templates for RF and power devices. Activity is minimal. Pricing and customers are not publicly disclosed.

Financial Narrative

Source basis:

  • Appendix 4E filings for FY2022, FY2023, FY2025 and FY2026

  • FY2025 Annual Report

  • H1 FY2026 Appendix 4D

Silex reports under Australian Accounting Standards (IFRS-aligned). Because GLE is equity-accounted, GLE's spending appears as a single line ("share of net loss of joint venture"). Gross profit, EBITDA and operating income are therefore not meaningful, and Silex does not report them. Those rows are left blank rather than estimated.

Income statement

Notes:

Revenue: FY2024–FY2026 figures are from the FY2025 and FY2026 Appendix 4E. FY2026 revenue includes ≈A$7.6M of GLE TRL-6 milestone revenue (FY2026 results presentation).

Margins. Gross, operating, EBITDA and net margins are not meaningful. Revenue consists of interest, milestones and services, and the net loss exceeds revenue in every year (FY2026 net loss/revenue ≈ -179%).

Revenue CAGR. FY2024–FY2026 revenue CAGR is ≈29% (12.91 → 21.59), but it is driven by one-off milestone income and higher interest income on a larger cash balance. It is not a commercial growth signal.

Commentary.

Loss trend: The net loss quadrupled from A$9.5M (FY2022) to A$42.6M (FY2025). This tracks GLE's ramp-up from the 2021 acquisition through TRL-6 testing (from May 2025), NRC licensing, PLEF site acquisition and preliminary site works.

FY2026 inflection: The FY2026 loss narrowed to A$38.6M. Higher revenue (the US$5M milestone) and higher interest income on the post-raise cash pile partly offset a larger share of GLE losses and higher employee expenses (FY2026 results).

H1 FY2026: Net loss attributable to owners was A$17.94M versus A$18.06M in H1 FY2025 (Appendix 4D, 25 February 2026). Run-rate losses appear to have stabilised around A$35–40M per year pre-FID.

Post-FID outlook: Losses would likely rise sharply after FID unless the PLEF is financed off Silex's balance sheet.

Balance sheet

Notes:

  • Debt excludes small lease liabilities (≈A$0.2–0.6M per aggregators). Silex reports "no corporate debt" (FY2026 results).

  • FY2025 equity is derived from the FY2026 statement that net assets of A$201.2M were "up 121%".

  • FY2025 share count is approximate and pre-placement: 276.7M after the placement and SPP, less ~33.3M placement shares and ~5.0M SPP shares.

Goodwill and intangibles, working capital and the short/long-term debt split are not separately verified. The balance sheet consists mainly of cash plus the equity-accounted investment in GLE. Aggregator data (Digrin/Seeking Alpha, US$) shows total liabilities of only about US$4.7–5.3M across recent periods, confirming a liability-light structure.

Commentary. Cash fell from A$113.1M (FY2024) to A$80.6M (FY2025), reflecting about A$32.5M of net outflow, chiefly contributions to GLE. The August 2025 placement (A$130M at A$3.90) and SPP (A$19.4M) took cash to A$180.7M at 30 June 2026. Management stated that the raise funds Silex "through FY2028" for its 51% share of GLE's commercialisation program (A$188.2M allocated) and other isotope projects (A$26.4M) (ASX, 7 August 2025). NTA per share nearly doubled to 72.26 cents.

Cash flow

Notes:

  • FY2026 change in cash is derived (180.70 - 80.56).

  • The FY2026 equity figure is the A$130M placement plus the ~A$19.4M SPP, before costs.

Operating cash flow, capex and free cash flow are not publicly disclosed in verified primary extracts. Capex at the parent level is small. Aggregators report half-yearly capex below US$0.1M; the Q-Si plant is the main parent-level capital item. Cash contributions to GLE sit in investing cash flows, as investment in a joint venture.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsLocation

Silex Systems

Parent-company technology development at Lucas Heights: SILEX R&D support for GLE, Q-Si project, MIST, corporate

Sydney (Lucas Heights), NSW

Silex USA

Holding of Silex's 51% interest in GLE; equity-accounted share of GLE losses and related US activities

North Carolina, USA

Translucent

Translucent Inc. — cREO (crystalline rare-earth oxide) semiconductor materials technology; minor activity

North Carolina, USA

Group Entities

EntityOwnershipRole

Silex Systems Limited

Listed parent

Owner and developer of SILEX IP

Silex USA (subsidiary)

100%

Holds GLE interest

Global Laser Enrichment Holdings LLC / Global Laser Enrichment LLC

51% Silex / 49% Cameco. Treated as jointly controlled and equity-accounted (Silex reports a "share of net loss of joint venture")

Exclusive SILEX uranium licensee; Wilmington NC Test Loop; PLEF developer

Translucent Inc.

100% (subsidiary)

cREO semiconductor materials

Results by Segment

Segment result (AUD Mn)FY2021FY2022FY2023FY2024FY2025FY2026

Silex Systems segment result

-3.8-1.8-1.9———

Silex USA segment result

-3.8-7.7————

Group net loss attributable to owners

-6.93-9.46-17.36-22.73-42.56-38.62

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from ordinary activities (AUD Mn)

——12.9112.2021.59

Other income (AUD Mn)

——4.336.41—

Net loss attributable to members (AUD Mn)

-9.46-17.36-22.73-42.56-38.62

Basic EPS (A$ cents)

———-17.9-14.2

Diluted EPS (A$ cents)

———-17.9-14.2

Dividends per share (A$ cents)

00000

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Cash, term deposits and dual-currency deposits (AUD Mn)

——113.0980.56180.70

Total corporate debt (AUD Mn)

00000

Net debt (AUD Mn; negative = net cash)

——-113.09-80.56-180.70

Net assets / equity (AUD Mn)

———91.0201.2

Net tangible assets per share (A$ cents)

——55.7038.2072.26

Shares on issue (millions)

———243277

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Change in cash and deposits (AUD Mn)

———-32.53100.15

Equity raised, gross (AUD Mn)

———0149.4

Dividends paid (AUD Mn)

00000

Buybacks (AUD Mn)

00000

Returns & Leverage Ratios (%)

RatioFY2025FY2026Comment

ROE (%)

—-26.4

Derived: -38.62 / average equity ((91.0 + 201.2)/2)

Debt/Equity (x)

00

No corporate debt

Revenue by Region

Region (revenue, AUD Mn)FY2024FY2025FY2026

Total revenue from ordinary activities

12.9112.2021.59

Valuation Snapshot

MetricValueSource / date

Share price

A$4.50

7 October 2026 (Kalkine)

52-week high (approx.)

A$10

November 2025

Year-to-date 2026

≈ -44% (to A$4.99)

Simply Wall St / Yahoo, ~September 2026

1-year TSR

+26.3%

Simply Wall St, ~September 2026

5-year TSR

+213.8%

Simply Wall St, ~September 2026

Market cap

~A$1.25B

At A$4.50 × 277.4M shares

Enterprise value

~A$1.07B

Market cap less A$180.7M cash

ADR (SILXY)

~US$16 (July 2026); 1 ADR ≈ 5 ordinary shares (inferred from SILXY/SILXF price ratio; verify with depositary)

StockAnalysis

Share Price

Price reference (AUD)May 2025Aug 2025Nov 2025Jan 2026Mar 2026Jul 2026Oct 2026

SLX share price

3.03.910.06.95.25.74.5

Valuation Multiples

MultipleSilexComment

P/E

Not meaningful (loss)

—

EV/Sales (FY2026)

≈50x

~A$1.07B / A$21.6M; not meaningful for valuation

P/B

≈6.2x

A$1.25B / A$201.2M net assets. Simply Wall St cited 6.9x at A$4.99

Analyst Conclusions

Guidance and expectations

Production timing: GLE targets tails re-enrichment at PLEF no later than 2030.

Licensing: The NRC targets the SER by January 2027, followed by a mandatory hearing.

Q-Si: Commissioning completes late 2026, with samples in Q1 CY2027.

Funding: Silex is funded through FY2028.

Financials: Consensus expects continued losses (EPS ~-A$0.13 next year).

Bull case

  1. Technology de-risked, licence in sight. TRL-6 is achieved, the NRC schedule is fixed (SER January 2027), and PLEF is the only new enrichment facility under licence review. A licence would remove the largest non-financial risk.

  2. Commercial architecture now in place. The Cameco exclusive offtake (September 2026), US$98.9M of state incentives and up to US$28.5M from DOE support an FID. A Cameco step-up to 75% would crystallise value for Silex's stake and shift capex funding to Cameco.

  3. Structural Western supply deficit. Russian supply exits by 2028, conversion and SWU are tight, and ~150M lb of U3O8-equivalent sits in DOE tails. The ≥7% royalty on a multi-million-SWU plant could be material relative to a ~A$1.1B EV.

Bear case

  1. Government capital went elsewhere. Losing the US$900M LEU award (January 2026) leaves GLE's owners to fund a roughly US$1.76B+ plant. Silex's 51% share far exceeds its A$180.7M cash, implying dilution unless Cameco exercises its option.

  2. Timeline slippage and first-of-a-kind risk. The target has moved from "as early as 2028" to "no later than 2030", and laser enrichment has never run commercially anywhere. Cost and schedule overruns are historically common in nuclear fuel-cycle projects.

  3. Valuation and signalling. At ~6x book with no recurring revenue, the stock prices in success. Directors sold ~A$10.8M of shares in February 2026, and the share price has fallen ~55% from its November 2025 peak.

Catalysts and monitorables (next 12 months)

CatalystExpected timingDirection
NRC final EIS issuanceLate 2026 (target was September 2026)Positive if on time
2026 AGM and Chair/CEO addressOctober–November 2026Neutral
Q-Si commissioning complete; first Si-28 samplesLate 2026 – Q1 CY2027Positive
NRC Safety Evaluation ReportJanuary 2027 targetMajor positive if on time
Mandatory hearing and licence decision2,027Binary
H1 FY2027 resultsFebruary 2027Cash burn check
Cameco 75% option decisionWindow to ~April 2028Potential major catalyst
PLEF feasibility, financing and FID2027 (unconfirmed)Binary
DOE contract execution for US$28.5M award; any new federal programsOngoingPositive
Uranium, conversion and SWU price trendsOngoingMacro

Analyst verdict

Silex Systems is a rare listed proxy for a genuinely differentiated nuclear fuel-cycle technology. The past 12 months delivered the most significant technical and commercial de-risking in its 38-year history. Independent validation of TRL-6 in October 2025 answered the long-standing question of whether laser enrichment works at scale. The NRC has set a firm review schedule. Kentucky has pledged up to US$98.9M of incentives. In September 2026, Cameco signed up as the exclusive buyer and seller of every product PLEF will make. On the evidence, the technology and commercial-channel risks are materially lower than at any prior point.

The equity has nonetheless de-rated by roughly 55% since November 2025. The January 2026 DOE outcome exposed the central unresolved problem: who funds a first-of-a-kind plant costing around US$1.76B. Silex's A$180.7M of cash funds its share of GLE only through FY2028, not through construction. Unless Cameco exercises its option to 75%, or the project secures substantial government-backed or project-level debt, Silex shareholders face significant dilution before the royalty stream begins around 2030. Timelines have already moved two years to the right, and director selling in February 2026 did little for sentiment.

At about A$1.1B of enterprise value, the market is pricing a meaningful but far from certain probability of PLEF reaching operation. The asymmetry is real. A ≥7% perpetual royalty plus a 51% equity interest in a multi-million-SWU plant, together with Q-Si optionality, could justify broker targets of A$11–13 on success. The downside on delay or financing failure is severe.

Verdict: speculative accumulate for risk-tolerant investors. Position sizing should reflect binary outcomes. The three decisive monitorables are the January 2027 SER, Cameco's option decision, and the PLEF financing structure. Until those resolve, Silex remains an option on US enrichment policy rather than a cash-flow story.


Sources consulted: - Silex Appendix 4E for FY2022, FY2023, FY2025 and FY2026 (ASX / OTC Markets)

  • FY2025 Annual Report summary (sustainabilityreports.com)

  • H1 FY2026 Appendix 4D and Operational Update (25 February 2026)

  • Operational Update (27 August 2026)

  • ASX announcements of 7 August 2025, 18 August 2025, 3 September 2025, 15 September 2025, 17 October 2025, 23 October 2025, 6 January 2026 and 27 March 2026

  • NRC Facility Finder and New Fuel Cycle Facility Licensing pages

  • Federal Register notices 2026-04474 and 2026-05955

  • GLE press release (August 2025)

  • ANS Nuclear Newswire (22 September 2026)

  • World Nuclear News

  • Secondary aggregators (flagged where used): Kalkine, Motley Fool Australia, Simply Wall St, Stockopedia, MarketScreener, InvestSMART, Quartr, StockAnalysis, Digrin, ROIC.ai, TipRanks, Market Index

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackgroundAge / born

Dr Michael P. Goldsworthy

CEO & Managing Director, Executive Director

Since Feb 1992 (~34 years)

Co-inventor of SILEX; BSc (Hons), MSc, PhD (physics); FAIP, GAICD. Also Chairman/CEO of Translucent Inc.

Born 1958

Julie E. Russell

CFO & Company Secretary

~15 years (since c.2011)

BBus, CA, MBA, GAICD

—

Dr Geordie Graetz

Chief Commercial Officer

—

MA, PhD

—

“—” = not publicly disclosed.

Board of Directors

NameRoleAppointedIndependenceBackground

Craig A. Roy

Non-Executive Chairman

Jan 2019

Independent

Former Deputy CEO of CSIRO (2010–2018); Chair, Australian Research Data Commons; NED, Sydney Water; Director of GLE Holdings LLC (chaired it until 31 Dec 2023); MBA (Macquarie)

Dr Michael P. Goldsworthy

CEO / MD

Feb 1992

Executive

See above

Christopher D. Wilks

Non-Executive Director

Sep 2007

—

Finance executive; extensive ASX board experience

Susan (Susie) Corlett

Non-Executive Director

Nov 2024

Independent

Public-company NED

Directors' Remuneration

ExecutiveSalary/fees (AUD)Total compensation (AUD)

Michael Goldsworthy (CEO)

~770,000

~1,180,000 (65% salary / 35% variable incl. equity)

Julie Russell (CFO)

Not separately verified

~731,000

Craig Roy (Chair)

~262,000

~262,000

Board & Management Changes

DateEvent

Nov 2024

Susie Corlett joins the board

15–16 Dec 2025

CEO exercises 562,500 options/performance rights; Majenta Holdings (Goldsworthy-associated entity) sells 562,500 shares at ~A$7.48 (~A$4.2M)

27 Feb 2026

Director sales: Goldsworthy (indirect) 650,000 shares at A$6.63 (~A$4.3M); Christopher Wilks 850,000 at A$6.63 (~A$5.6M); Craig Roy 129,507 at ~A$6.90 (~A$0.9M)

Major Shareholders

Substantial / notable holders (most recent disclosures)Stake / activity

Van Eck Associates Corporation

Became substantial holder at 5.39% (>12.8M shares); active trading through Nov 2025

State Street Global Advisors

Ceased substantial holding 17 Nov 2025; active buying Dec 2025 (e.g., +2.4M shares, 19 Dec 2025)

BNY Asset Management

Buying Mar 2026 (small)

JPMorgan Chase & Co.

Trading around Aug 2025 placement

Competitive Landscape

Competitors by Segment

SegmentCompetitorTechnologyPositioning vs SILEX/GLE

Uranium enrichment

Urenco (UK/NL/DE; Urenco USA, Eunice NM)

Gas centrifuge

Incumbent Western leader; expanding US capacity

Uranium enrichment

Orano (France; planned Oak Ridge, TN "Project IKE")

Gas centrifuge

Major incumbent; US expansion

Uranium enrichment

Rosatom / TENEX (Russia)

Gas centrifuge

Largest global capacity; US import ban and waivers phasing out

Uranium enrichment

CNNC (China)

Gas centrifuge

Large domestic supplier

Uranium enrichment / HALEU

Centrus Energy (US; Piketon, OH)

AC100M centrifuge

Only US-owned enricher; HALEU producer; DOE-backed

Uranium enrichment

General Matter (US; Paducah lease, Aug 2025)

—

New entrant at the same Paducah locale

Conversion / UF6 supply

ConverDyn/Honeywell (Metropolis), Cameco (Port Hope), Orano

Conversion

PLEF tails re-enrichment produces natural UF6, competing with conversion-plus-mining supply

Uranium supply

Kazatomprom, Cameco, NexGen and others

Mining

Tails-derived UF6 competes as secondary supply

Enriched silicon

Russian centrifuge-enriched Si-28 suppliers (historical), URENCO stable isotopes

Centrifuge

Silex claims a laser route offers secure non-Russian supply

Medical isotopes (Yb-176)

Isotope suppliers (e.g., Russian centrifuge supply; ASP Isotopes)

Centrifuge / laser (ASP's QE-LIS)

Emerging competition in laser isotope separation

“—” = not publicly disclosed.

Peer Comparison FY2026

CompanyRevenueGrowthMargin profileR&D intensity

Silex Systems (FY2026)

A$21.6M

+77%

Loss-making (net loss A$38.6M)

Very high (most spend is R&D via GLE)

Centrus Energy (FY2025)

——

Profitable (LEU trading plus HALEU contract)

Moderate

Urenco (FY2025)

——

High EBITDA margins (enrichment oligopoly)

Low–moderate

Orano (FY2025)

——

Profitable

Moderate

Company Snapshot

1987

Founded

Lucas Heights, Australia

Headquarters

SWOT Analysis

Strengths

  • TRL-6 achieved and independently validated on 23 October 2025 (ASX announcement), de-risking core technology.
  • Net cash of A$180.7M and no corporate debt at 30 June 2026 (FY2026 Appendix 4E), funded through FY2028 (ASX, 7 August 2025).
  • Exclusive Offtake Agreement with Cameco for all PLEF output, September 2026 (Silex website; ANS, 22 September 2026).
  • Layered economics: ≥7% perpetual royalty plus up to US$20M in milestones plus 51% equity in GLE (company disclosures).
  • PLEF licence application accepted 4 August 2025; NRC schedule set (EIS September 2026, SER January 2027) by CLI-26-3.
  • Government support: up to US$28.5M from DOE (January 2026) and up to US$98.9M in Kentucky incentives (March 2026).
  • Founder-led continuity: CEO and co-inventor since 1992 (ASX director data).

Weaknesses

  • Negligible commercial revenue: A$21.6M in FY2026, including a one-off ≈A$7.6M milestone.
  • Persistent losses: A$42.6M (FY2025) and A$38.6M (FY2025 and FY2026 Appendix 4E).
  • Cameco is the commercial lead and holds a 75% step-up option, limiting Silex's strategic control.
  • No disclosed project capex or financing plan for PLEF; the Kentucky package references an investment of about US$1.76B.
  • Director selling of ~A$10.8M on 27 February 2026 (Appendix 3Y), a poor signalling optic.
  • Long board tenures (average ~20 years per Simply Wall St) and an ISS Shareholder Rights pillar score of 1, which on the ISS scale means lowest governance risk on that pillar (ISS, May 2024). The Compensation pillar score of 4 is the weaker area.

Opportunities

  • Western enrichment supply deficit and Russian import phase-out.
  • Tails re-enrichment could unlock ~150M lb of U3O8-equivalent (Shaw and Partners, July 2026).
  • LEU+ and HALEU demand from advanced reactors and SMRs.
  • Cameco option exercise (26% stake) would crystallise value and reduce Silex funding obligations.
  • Q-Si first samples (Q1 CY2027) could open a high-value niche.
  • MIST entry into the Lu-177 supply chain.

Threats

  • Missed US$900M DOE LEU award; capital flowed to competitors (ASX, 6 January 2026).
  • First-of-a-kind scale-up and cost overruns; target timing has already moved from "as early as 2028" to "no later than 2030".
  • Licensing delays or adverse hearing outcomes.
  • Uranium and SWU price downturn, which would weaken tails economics.
  • US policy reversal or loss of funding support.
  • Competition at Paducah (General Matter) and centrifuge expansions (Urenco USA, Orano Project IKE, Centrus).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr 2025GLE receives a DOE award/selection under an enrichment program (FY2025 AR reference)Early federal engagement
May 2025GLE begins large-scale TRL-6 enrichment testing at WilmingtonStart of key de-risking program
13 Jun 2025PLEF Environmental Report submitted to NRCLicensing start
27 Jun–1 Jul 2025PLEF Safety & Safeguards Analysis Report submittedLicence application complete
FY2025~700-acre Paducah site acquiredSite control
4 Aug 2025NRC accepts PLEF application for formal reviewRegulatory milestone
7 Aug 2025A$130M placement at A$3.90Funding through FY2028
Aug 2025DOE issues LEU acquisition solicitation; GLE bids (due early September 2025)Led to the January 2026 outcome
27 Aug 2025FY2025 results: net loss A$42.6M (+87%); cash A$80.6MPeak loss year
29 Aug / 3 Sep 2025SPP closes, raising ~A$19.4M (oversubscribed versus A$15M target)Retail support
5 Sep 2025NRC opens EIS scoping (comments to 6 October 2025)NEPA process
15 Sep 2025Notice of 2025 AGMGovernance
17 Oct 2025AGM; all resolutions carriedGovernance
23 Oct 2025GLE achieves TRL-6Major de-risking; starts Cameco option clock
Nov 2025SLX trades above A$10 at the peak (e.g., Van Eck trades at ~A$10.08–10.35)Valuation peak
17–19 Nov 2025State Street ceases substantial holding; 110,037 shares issued under the employee incentive planRegister changes
Dec 2025US$5M TRL-6 milestone received from GLEFirst milestone cash
6 Jan 2026GLE wins up to US$28M DOE innovative technology award but misses the US$900M LEU award; SLX falls >29% to ~A$6.93Major sentiment reset
25 Feb 2026H1 FY2026 results: net loss A$17.9MStable burn
27 Feb 2026Director share sales (CEO-associated, Wilks, Roy) totalling ~A$10.8MNegative signalling optics
4 Mar 2026NRC Commission Order CLI-26-3 sets review scheduleLicence timeline clarity
6 Mar 2026Federal Register notice of hearing/receipt for PLEF applicationFormal process
2026 (H1 CY)NRC issues draft EIS for public comment (Docket NRC-2025-1007)Environmental review progressing
27 Mar 2026Up to US$98.9M Kentucky/McCracken incentives (preliminary approval)Project economics support
2026Q-Si plant construction completed; commissioning beginsSecond platform milestone
13 Jul 2026Shaw and Partners target A$12.80 (versus ~A$5.74)Broker support
27 Aug 2026FY2026 results: revenue A$21.6M (+77%); loss A$38.6M; cash A$180.7MStronger balance sheet
Sep 2026GLE–Cameco exclusive Offtake Agreement for all PLEF outputCommercial pillar for FID
Sep 2026 (scheduled)Final EIS target date per CLI-26-3Monitorable (completion not confirmed in sources)
7 Oct 2026SLX at A$4.50~55% below the November 2025 peak

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Results by Segment: Silex Systems segment result rose from AUD -3.8 Mn in FY2021 to AUD -1.9 Mn in FY2023.
Silex Systems Limited — Results by Segment
Series (AUD Mn)FY2021FY2022FY2023FY2024FY2025FY2026
Silex Systems segment result-3.8-1.8-1.9———
Silex USA segment result-3.8-7.7————
Group net loss attributable to owners-6.9-9.5-17.4-22.7-42.6-38.6

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.